A61K 31/708
Having oxo groups directly attached to the purine ring system
Official title: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K31/708 (Having oxo groups directly attached to the purine ring system) appears on 366 US grants and 596 published applications in this corpus.
Search patents in A61K- Granted patents
- 366
- Published applications
- 596
- Assignees
- 326
- Inventors
- 1,168
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 0 | 0 |
| 1997 | 7 | 0 |
| 1998 | 7 | 0 |
| 1999 | 4 | 0 |
| 2000 | 11 | 0 |
| 2001 | 2 | 2 |
| 2002 | 10 | 21 |
| 2003 | 11 | 18 |
| 2004 | 7 | 15 |
| 2005 | 5 | 15 |
| 2006 | 2 | 14 |
| 2007 | 10 | 18 |
| 2008 | 5 | 12 |
| 2009 | 8 | 15 |
| 2010 | 7 | 19 |
| 2011 | 8 | 17 |
| 2012 | 11 | 25 |
| 2013 | 7 | 30 |
| 2014 | 20 | 43 |
| 2015 | 21 | 27 |
| 2016 | 24 | 29 |
| 2017 | 19 | 29 |
| 2018 | 14 | 32 |
| 2019 | 30 | 32 |
| 2020 | 22 | 23 |
| 2021 | 22 | 39 |
| 2022 | 16 | 31 |
| 2023 | 20 | 26 |
| 2024 | 11 | 25 |
| 2025 | 12 | 17 |
| 2026 | 9 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus22 Sep 2026US 12,741,984 B2Atea Pharmaceuticals, Inc.
- Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools18 Aug 2026US 12,708,642 B2Ucb Biosciences, Inc.
- Methods of treating cancer by suppression of FAMIN expression21 Jul 2026US 12,686,866 B2Cambridge Enterprise Limited
- Adenosine analog and its use in regulating the circadian clock30 Jun 2026US 12,667,584 B2National Institute of Biological Sciences, Beijing
- Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection7 Apr 2026US 12,594,288 B2Abbott Laboratories
- Substituted bicyclic heterocycle compounds, compositions, and uses thereof1 Oct 2026US 2026/0294949 A1
- Adenosine analog and its use in regulating the circadian clock1 Oct 2026US 2026/0294952 A1National Institute of Biological Sciences, Beijing
- Composition for use for improving or preserving mental health in canine24 Sep 2026US 2026/0284093 A1Mars, Incorporated
- Pyrimidine nucleoside treatments27 Aug 2026US 2026/0248833 A1Children's Medical Center Corporation
- Medicament for preventing and treating tumor and use thereof23 Jul 2026US 2026/0207647 A1Beijing Hospital
Most cited
By later US patents
- 2′-Fluoronucleosides184US 6,348,587 B1Emory University · 2002
- Methods and compositions for treating hepatitis C virus173US 6,914,054 B2Idenix Pharmaceuticals, Inc. · 2005
- Methods and compositions for treating hepatitis C virus162US 7,608,597 B2Idenix Pharmaceuticals, Inc. · 2009
- Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections149US 7,608,600 B2Centre National De La Recherche Scientifique · 2009
- 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication.143US 6,784,166 B2Syntex (U.S.A.) Inc. · 2004